Chronic Lymphocytic Leukemia

New Reference: Zanubrutinib in CLL

2023-06-14

  • Study

    Open-label, multicentre, phase 3 study
    Untreated CLL or SLL
    Patients without del (17) (p13·1)  zanubrutinib (group A; n=241) or bendamustine–rituximab (group B; n=238) and patients with del(17) (p13·1) zanubrutinib

  • Efficacy

    mPFS was significantly improved in group A versus group B (HR 0·42 [95% CI 0·28 – 0·63]; p<0·0001)
    24 months PFS: 85·5% in group A and 69·5% in group B
    ORR: 94·6% in group A and 85·3% in group B
    CR rate: 7% in group A and 15% in group B

  • Safety

    Grade 1-2 any AEs: 41% vs 16% (group A vs group B)
    Grade ≥3 AEs neutropenia 11% vs 51%, infections 16% vs 19%
    Grade 1-2 all bleeding AE: 41% vs 9%


    • Lancet Oncol. 2022 Aug;23(8):1031-1043

    {“Constantine S.T etal.”}Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

    http://doi.org/10.1016/s1470-2045(22)00293-5

    Reviewed by Hasan Cagri Yildirim, MD on Nov 26, 2022